


Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-May-2021  
Document Type: USP Monographs  
DocId: GUID-95991A0F-0142-4945-B39B-3931911EC151\_5\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M54521\\_05\\_01](https://doi.org/10.31003/USPNF_M54521_05_01)  
DOI Ref: 0dln7

© 2025 USPC  
Do not distribute

## Modafinil



$C_{15}H_{15}NO_2S$  273.35

Acetamide, 2-[(diphenylmethyl)sulfinyl]-;

2-[(Diphenylmethyl)sulfinyl]-acetamide CAS RN<sup>®</sup>: 68693-11-8; UNII: R3UK8X3U3D.

### DEFINITION

Modafinil contains NLT 98.0% and NMT 101.5% of modafinil ( $C_{15}H_{15}NO_2S$ ), calculated on the anhydrous basis.

### IDENTIFICATION

**Change to read:**

- **A. SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy:** 197K ▲ or 197A ▲ (USP 1-May-2021)

**Add the following:**

- ▲ • **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay. ▲ (USP 1-May-2021)

### ASSAY

**Change to read:**

#### • PROCEDURE

**Buffer:** 6.8 g/L of [potassium dihydrogen phosphate](#) in [water](#). Adjust with [phosphoric acid](#) to a pH of 2.3.

**Mobile phase:** [Acetonitrile](#) and *Buffer* (35:65)

**Diluent:** [Acetonitrile](#) and [water](#) (35:65)

**System suitability solution:** 5 µg/mL of [USP Modafinil RS](#) and 10 µg/mL of [USP Salicylic Acid RS](#) in *Diluent*

**Standard solution:** 0.1 mg/mL of [USP Modafinil RS](#) in *Diluent*

**Sample solution:** 0.1 mg/mL of Modafinil in *Diluent*

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 220 nm

**Column:** 4.6-mm × 15-cm; 5-µm packing [L1](#)

**Column temperature:** 40°

**Flow rate:** 1 mL/min

**Injection volume:** 20 µL

#### System suitability

**Sample:** *System suitability solution*

[NOTE—The relative retention times for modafinil and salicylic acid are about 1.0 and 1.1, respectively.]

#### Suitability requirements

**Resolution:** NLT 1.3 between modafinil and salicylic acid

**Tailing factor:** NMT 1.5 for the modafinil peak

**Relative standard deviation:** NMT ▲0.73% ▲ (USP 1-May-2021) for the modafinil peak

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of modafinil ( $C_{15}H_{15}NO_2S$ ) in the portion of Modafinil taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of modafinil from the *Sample solution*

$r_S$  = peak response of modafinil from the *Standard solution*

$C_S$  = concentration of [USP Modafinil RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Modafinil in the *Sample solution* (mg/mL)

**Acceptance criteria:** 98.0%–101.5% on the anhydrous basis

#### IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

**Change to read:**

- **ORGANIC IMPURITIES**

**Buffer, Mobile phase, ▲Diluent,▲** (USP 1-May-2021) **System suitability solution, Sample solution, and Chromatographic system:** Proceed as directed in the Assay.

**▲Sensitivity solution:** 0.05 µg/mL of [USP Modafinil RS](#) in *Diluent*▲ (USP 1-May-2021)

#### System suitability

**Samples:** *System suitability solution*▲ and *Sensitivity solution*▲ (USP 1-May-2021)

#### Suitability requirements

**Resolution:** NLT 1.3 between modafinil and salicylic acid, ▲*System suitability solution*▲ (USP 1-May-2021)

**Tailing factor:** NMT 1.5 for the modafinil peak, ▲*System suitability solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*▲ (USP 1-May-2021)

#### Analysis

**Sample:** *Sample solution*

Calculate the percentage of each ▲individual▲ (USP 1-May-2021) impurity in the portion of Modafinil taken:

$$\text{Result} = (r_U/r_T) \times (1/F) \times 100$$

$r_U$  = peak response of each individual impurity

$r_T$  = sum of the responses of all the peaks

$F$  = relative response factor (see [Table 1](#))

**Acceptance criteria:** See [Table 1](#). ▲The reporting threshold is 0.05%.▲ (USP 1-May-2021)

**Table 1**

| Name                                      | Relative Retention Time | Relative Response Factor | Acceptance Criteria, NMT (%) |
|-------------------------------------------|-------------------------|--------------------------|------------------------------|
| Modafinil                                 | 1.0                     | —                        | —                            |
| Salicylic acid <sup>a</sup>               | 1.1                     | —                        | —                            |
| Modafinil acid <sup>b</sup>               | 1.4                     | 1.0                      | 0.5                          |
| Modafinil sulfone <sup>c</sup>            | 1.7                     | 0.9                      | 0.5                          |
| Modafinil ester <sup>d</sup>              | 3.0                     | 1.0                      | 0.5                          |
| Any other individual unspecified impurity | —                       | 1.0                      | 0.05                         |
| Total impurities                          | —                       | —                        | 1.0                          |

<sup>a</sup> Salicylic acid is used for calculating resolution and is not a potential impurity.

<sup>b</sup> 2-[(Diphenylmethyl)sulfinyl]acetic acid.

<sup>c</sup> 2-[(Diphenylmethyl)sulfonyl]acetamide.

<sup>d</sup> 2-[(Diphenylmethyl)sulfinyl]acetic acid methyl ester.

SPECIFIC TESTS

- [WATER DETERMINATION \(921\)](#), [Method I](#): NMT 0.2%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at controlled room temperature.
- **USP REFERENCE STANDARDS (11).**  
[USP Modafinil RS](#)  
[USP Salicylic Acid RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact                                       | Expert Committee          |
|----------------|-----------------------------------------------|---------------------------|
| MODAFINIL      | <a href="#">Documentary Standards Support</a> | SM52020 Small Molecules 5 |

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. 45(5)

**Current DocID:** GUID-95991A0F-0142-4945-B39B-3931911EC151\_5\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M54521\\_05\\_01](https://doi.org/10.31003/USPNF_M54521_05_01)

**DOI ref:** [0dln7](#)

OFFICIAL